FL-ELEVATE-PRIZE
4.11.2021 17:02:13 CET | Business Wire | Press release
The Elevate Prize Foundation, in collaboration with MIT Solve, announced today the winners of the second annual Elevate Prize, which distributes $5 million across 10 diverse social entrepreneurs working to solve pressing issues around the world. This year’s winners, selected from a pool of over 1,200 applicants, stand out for their innovative approaches to global causes, such as LGBTQIA+ rights, access to health care, social justice reform and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005942/en/
Founded in 2019 by Joseph Deitch, The Elevate Prize Foundation aims to “Make Good Famous” by partnering with rising activists and social entrepreneurs and providing them with resources to raise visibility of their work, multiplying their ability to mobilize support – whether online or on-the-ground. The 2021 winners of the Elevate Prize will each receive a minimum of $300,000 in prize funding, as well as leadership development services, social media training, mentorship, and other support needed to reach a wider audience and grow their following.
“This year’s Elevate Prize winners are an exceptional group of creative problem-solvers who have managed to catalyze change through such challenging times,” said Joseph Deitch, Founder, Elevate Prize Foundation. “In a world that is increasingly looking for leaders to lead … and to inspire us, we are so fortunate to have these incredible individuals and organizations show us the way. We look forward to partnering and co-creating with them to expand their impact, and to share their stories with the world.”
The winners of the 2021 Elevate Prize are:
- Amanda Alexander, Detroit Justice Center , which works alongside communities to transform the justice system and promote equitable and fair cities.
- Krista Donaldson, Equalize Health , which provides access to medical care and addresses the leading causes of maternal and newborn mortality through innovative tech.
- Aparna Hegde, ARMMAN , which uses mobile technology to enable healthy pregnancies, safe deliveries, and healthy childhoods.
- Kaushik Kappangantulu, Kheyti , which designs, adapts and implements low-cost farming solutions to help farmers increase yield and predictability of produce, offering a “greenhouse-in-a-box” – an affordable, modular greenhouse bundled with full-stack services.
- Nisha Ligon, Ubongo , the leading children’s entertainment producer in Africa, which harnesses the power of entertainment to reduce inequalities in education across Africa.
- Heejae Lim, TalkingPoints , which connects and empowers families in under-resourced, multilingual communities, using communications technology to bridge crucial gaps between students, families, teachers, and schools.
- Uzoma Orchingwa , Ameelio , which works to reduce the prison population, decrease recidivism and ensure incarcerated individuals can stay in touch with the outside through free-to-use communication apps.
- Alexander Roque, Ali Forney Center , a space dedicated to empowering homeless LGBTQIA+ youth to live independently and get back on their feet.
- Rebecca van Bergen, Nest , which supports the responsible growth and creative engagement of the artisan and maker economy to build a world of greater gender equity and economic inclusion.
- Tony Weaver , Weird Enough Productions , which runs a national education program that combines diverse comic books with an anti-racist and equity-based learning curricula.
“We’re thrilled to highlight such a radically diverse group of winners this year, all working on a wide-range of important issues around the world,” said Carolina García Jayaram, CEO of The Elevate Prize Foundation. “We look forward to helping grow their audience and impact, ultimately making philanthropy and social change more accessible to all.”
The Elevate Prize 2021 winners were selected by a renowned judging panel, composed of purpose-driven leaders in business, academia, media and beyond, including Diane von Furstenberg, fashion designer and philanthropist; Maria Elena Salinas, journalist and CBS news contributor; Stephanie Mehta, Editor-in-Chief of Fast Company; and Natalie Tran, Executive Director of the CAA Foundation.
About The Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, The Elevate Prize Foundation aims to serve as an engine for social good by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize, which is awarded to 10 or more global leaders tackling pressing issues in innovative ways. The Elevate Prize Catalyst Award, another one of the Foundation’s programs, recognizes prominent individuals for their commitment to inspiring global social action and using their influence for the good of humanity. Through the Elevate Giving program, the Foundation allows everyday people the opportunity to engage in philanthropy. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook , Instagram , LinkedIn , and Twitter .
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
